Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of SFX-01 in ER-positive, HER2-negative metastatic breast cancer after endocrine progression
2015-004851-28Phase 2Completed
- Sponsor
- TheraCryf
- Start
- Jun 2016
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sulforadex in breast cancer, sponsored by TheraCryf. Started Jun 2016; status: completed.
02
Drugs
sulforadex
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2015-004851-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004851-28.